News
More Than Half of U.S. Adults Could Benefit from GLP-1 Medications, Researchers Find
BIDMC researchers find that 137 million adults are eligible for semagludtide for weight loss, diabetes management or prevention of recurrent cardiovascular events.
Nov. 20, 2024
Read More About:
